Company / R&D Expense
Vera Therapeutics, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$215.3M
FY2025
5-year range
$22.5M / $215.3M
FY2021-FY2025
Trend
+70.6%
vs FY2024
Sector context
#79 of 210
Health Care
What the data says
At $215M, Vera Therapeutics, Inc.'s r&d expense ranks #79 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $22M in FY2021 to $215M in FY2025.
Based on SEC 10-K filings.
$215M in FY2025 with a 5-year CAGR of +36.6%.
Improved from $78M to $215M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +46.1%
- 5-Year CAGR
- +36.6%
- 10-Year CAGR
- -
Sector benchmark
#79 of 210 in Health CareTop 38% of 210This company $215.3M Sector average $644.1M
▼
-66.6% below sector average
Key checks
Key Insights
- Vera Therapeutics, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +36.6%, indicating consistent growth.
- In FY2025, r&d expense increased 70.6% year-over-year.
- Ranks #79 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $215.3M | +70.6% |
| FY2024 | $126.2M | +61.3% |
| FY2023 | $78.2M | +13.4% |
| FY2022 | $69.0M | +206.9% |
| FY2021 | $22.5M | -50.3% |
| FY2020 | $45.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026